Author: openjargon

  • Memorial Day weekend marred by severe weather — and it’s not over

    Powerful storm leaves building badly damaged
    Powerful storm rips through Valley View, Texas

    • Memorial Day weekend was marred by severe storms across the US.
    • More than 20 people died, and tornado warnings are in effect for Maryland, Texas, and other states.
    • Scientists blame the heat and say the severe weather will continue. 

    Memorial weekend is the unofficial start of summer, and this year it was marred by a series of severe weather incidents that scientists say could continue as temperatures rise.

    Severe weather, including thunderstorms and tornados, swept across Texas, Oklahoma, Arkansas, and Kentucky over the holiday weekend, destroying buildings and killing over 20 people, according to the Associated Press.

    Andy Beshear, the governor of Kentucky, declared a state of emergency on Monday after five people died in the state from incidents associated with the severe weather.

    The storms moved to the Northeast on Memorial Day, placing the Washington, DC, metropolitan area under a tornado watch on Monday evening. Parts of Texas, the Lower Great Lakes, and the Mid-Atlantic continue to be under a tornado watch for Tuesday, the National Weather Service said.

    The NWS warned of flash flooding in the Northeast and Mid-Atlantic region on Monday, and hail in the Southern Plains and Texas on Tuesday and possibly Wednesday.

    Semi truck damaged in Texas storm
    Severe weather damages a truck stop in Texas

    Harold Brooks, a senior scientist at the National Severe Storms Laboratory in Norman, Oklahoma told the AP that a persistent pattern of warm, moist air is behind the string of tornadoes over the past two months.

    Sjoukje Philip, a researcher at the Royal Netherlands Meteorological Institute, said that while attributing tornadoes to climate change is not straightforward, there is a link.

    "With hotter sea surface temperatures, the air can hold more moisture. So I can also imagine that whenever there is precipitation, whether that's from a tornado or something else, there can be more rainfall, on shorter timescales. So that's a really clear relation," Philip told the AP.

    The series of storms comes as temperatures climb in parts of the US, including Texas, where weather forecasters predicted temperatures of up to 120 degrees Fahrenheit this weekend in some parts of the state. And just last week, in Mexico, temperatures got so hot that multiple monkeys suffered heat stroke and were dropping from trees like apples.

    Philip noted that 2023 was the hottest year on record and that average temperatures are expected to continue to rise, which could trigger more severe weather.

    Read the original article on Business Insider
  • The greats you should base your investing on

    following famous investors in shares represented by pair of men's business shoes

    “Dad, you wave at people a lot when you’re driving. I think it’s because you’re old.”

    Now, as much as I’d like to believe my son was wrong about that first statement, I’m not sure he is.

    A driver coming the other way had pulled further to his left to give me room to go around some workers on the side of the road. So yes, I waved in acknowledgement and thanks.

    It did give me the opportunity to talk to my son about being kind, and thankful. And that I try to be considerate in return. I told him that my hope is also that by being considerate, and appreciating others when they are, too, it might lead, in a very small way, to a slightly nicer community.

    And it reminded me of driving in the country. We try to get away for a few weeks every winter in the school holidays – recently that’s been a series of driving holidays in the bush. If you’ve done the same, you’ll know that there’s a very strong correlation between the distance from a capital city, and the likelihood that you’ll get a wave from an oncoming driver.

    Obviously impractical around town – you’d get RSI just going to and from work – but in the bush there’s something really nice about acknowledging each other in that very small way.

    Surprise, surprise: after I dropped the young bloke off at school, my thoughts turned to investing.

    It reminded me of what might be my favourite quote of all time (it’s a crowded field, and I reserve the right to change my mind!), from Sir Isaac Newton:

    “If I have seen further than others, it is by standing upon the shoulders of giants.”

    This statement of absolute humility, from one of the greatest minds humanity has known, has always struck me.

    None of us can do it – anything – all alone.

    We are the product of our lives up to this point:

    Parents, siblings, extended family, friends, neighbours, teachers, colleagues, managers, coaches, teammates, books, television shows, opportunities, obstacles, successes, failures…

    There is no self-made man or woman. There is no overnight success. None of us achieves anything from first principles.

    Which, frankly, we should find wonderfully freeing. It should free us from our own egos. And lower the heights of the mountains we aim to climb.

    The humility to stand on the shoulders of giants – to learn from others, and use their example and expertise – also gives us an enormous advantage.

    Investors don’t have to divine for ourselves the mathematical concepts behind the ‘discounted cash flow‘ model. We don’t have to invent the term ‘competitive advantage’. We don’t need to discover the beauty of a capital-light business model. Or the benefits of economies of scale. And much more, besides.

    Indeed, we have never had more information – and access to that information – including the ideas, successes and failures of those who came before.

    It would be hubris in the extreme to think that we can find or invent some heretofore unknown investing principle or paradigm. And even if we could, the time and effort it would take would almost certainly be better used understanding what is already known, and putting it to work for ourselves.

    And yet, it is that very hubris (and/or ego) that leads many to ignore what is already known. It is behind the ‘not invented here’ syndrome that inflicts much of society. And, frankly, we see it all too often in the ‘Warren Buffett’s lost it’ headlines, and the idea that ‘old fashioned’ investing principles don’t apply for one reason or another.

    (Indeed… the increase in such sentiment is an interesting sign that investors may be getting carried away. No, don’t use it to try to time the market, but do be careful if you feel yourself getting caught up in something!)

    Me? I don’t think I’ve ever had an original idea about an investing principle. About how they might apply, sure. But there is no ‘Phillips Constant’ or ‘Phillips Trading Strategy’. I think I’ve done okay applying existing principles, but not inventing my own.

    I’ve written this before, but I am almost never the smartest person in the room (sometimes, not even when I’m alone!). If I have a skill, or perhaps more accurately an ‘approach’ that works, it’s in doing my best to synthesise the ideas of others and apply them to new circumstances.

    I’ve taken the maths of Ben Graham, the sensibility of Warren Buffett, the multidisciplinary brilliance of Charlie Munger, the explanations of Peter Lynch, the business savvy of Jim Collins and the behavioural insights of Danny Kahneman and Amos Tversky. I’ve read countless others who have unpacked and explained all of the above, and more. And I’ve internalised Aesop’s ‘Tortoise and the Hare’, both as a general principle and as encapsulated in my single favourite investment picture: The Vanguard 30-Year Index Chart.

    There are a lot of giants in the paragraph above. Neither you nor I could hope to become any one of them via our own efforts in a single lifetime – and certainly not all of them.

    And to return to my original point, each of those people has paid their expertise forward – in their writing, speaking, and in their example and results. The beauty of knowledge is that it is, like investing, a compounding phenomenon: the more you know, the more you can know.

    I do this job in large part because I was fortunate enough to learn from my now-colleagues in the US, when I was starting out as an investor. And because I can repay that by paying it forward to others.

    More giants. More shoulders.

    So, this is my acknowledgement of them. And my hope is that by sharing it, others will be able to access the lessons I’ve learned.

    I had a lovely message from a reader the other day, thanking me for what I do in this space and on our podcast, Motley Fool Money. He wanted to send me a small gift as a thank you.

    Which is flattering, obviously. And very much appreciated. But I asked him, instead, to just pay it forward – to share what he’s learned and benefitted from, with others.

    No, I don’t think I’m going to unleash a new wave of waving drivers. Or a wave of investors who’ve had their own Damascene conversions. But if I can make a bit of a difference, for a few people, I’ll consider my work done.

    And the ‘old’ bit of my son’s comment? I’m just going to have to cop that one on the chin!
    Fool on!

    The post The greats you should base your investing on appeared first on The Motley Fool Australia.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now…

    See The 5 Stocks
    *Returns as of 5 May 2024

    More reading

    Motley Fool contributor Scott Phillips has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • Disengaged voters could be the key to Biden winning a second term. But they need to be convinced on the economy.

    Biden
    President Joe Biden speaks about investing in clean energy manufacturing at CS Wind in Pueblo, Colorado.

    • A new poll shows Trump's polling gains have been powered by voters who didn't cast a ballot in 2020.
    • The Times says these voters could stay home or return to Biden. 
    • Many of these voters actually lean Democratic, but they've drifted away from Biden over the economy.

    President Joe Biden's reelection chances could rest on the support of irregular and disengaged voters — a segment of the population who sat out the hotly-contested 2020 presidential race.

    But Biden would have to convince these voters that his vision for the economy would ultimately work for them, as their lagging support for his campaign has given former President Donald Trump a major opening ahead of November.

    A New York Times/Siena College poll released last month shows Trump's polling gains have been powered by registered voters who didn't vote in 2020. Among these so-called irregular voters, Trump had a seven-point advantage over Biden (43% to 36%) for the 2024 contest in the latest poll. And Trump held an overall one-point lead (46% to 45%) among registered voters, while Biden had a one-point lead over Trump among voters aged 18 to 29.

    However, there's no guarantee these voters will remain in Trump's corner in November, the Times wrote. With many irregular voters splitting their tickets — which is already being seen as Democratic Senate candidates in swing states including Pennsylvania and Wisconsin are running ahead of Biden — Trump's support among these disengaged voters could falter as partisan leanings sharpen closer to the election. Many of these less engaged voters could eventually support Biden or stay at home, said the Times.

    A big issue for irregular voters appears to be the economy, the poll showed. Democratic-leaning irregular voters said they view the economy as either "poor" or "fair," while Democratic voters who vote more regularly, described the economy as "good" or "excellent," the report said.

    This presents a challenge for Biden as he aims to bolster his economic message — especially among young voters and minorities who would generally be inclined to back him based on prior voting trends. In the 2020 election, Biden dominated among young voters aged 18 to 29, winning this group by 24 points over Trump, according to Pew Research.

    But as recent data has showed, the 2024 race will be fought on much different terrain than the 2020 contest.

    Read the original article on Business Insider
  • Cockroaches wouldn’t exist without humans. We helped them become one of the world’s worst pests, according to a new study.

    German cockroach
    A German cockroach on a piece of bread.

    • The German cockroach is one of the most common household pests worldwide.
    • New research found that the species evolved to thrive in human dwellings about 2,100 years ago.
    • "It's a creation of human-made environments," a researcher told the Washington Post.

    If you ever saw a cockroach scuttling across your kitchen floor or a restaurant wall, chances are it was a German cockroach. The German roach is the most common of the 70 different cockroach species in the US.

    For 250 years, scientists didn't know where it came from and how it managed to spread to every continent on Earth except Antarctica. Now that mystery has been solved, and the answer is that it's largely our fault.

    The German cockroach is "a creation of human-made environments," Edward Vargo, an entomology professor at Texas A&M University and co-author of a new study identifying the roach's origins, told The Washington Post.

    The German cockroach can't survive in "temperate winters outdoors" and all species of cockroaches "prefer warm, moist places where they can feed on human and pet foods, decaying and fermenting matter, and a variety of other items," according to the Illinois Department of Public Health.

    That's why it's pretty safe to say that if human-built establishments like houses, stores, restaurants, and other buildings didn't exist, neither would these pesky pests.

    The researchers published their results last week in the peer-reviewed journal Proceedings of the National Academy of Sciences.

    Where did the German roach come from?

    Scientists have long understood that the species thrive indoors, but their origins remained a mystery.

    Through DNA analysis, Vargo and his colleagues found that the species' closest relative is the Asian cockroach.

    The German roach evolved from its Asian cousin about 2,100 years ago to adapt to "human settlements in India or Myanmar," the researchers reported in their paper.

    With advancements in transportation and "temperature-controlled housing," the German cockroach made its relatively recent global spread, the researchers said in their report.

    How the German cockroach took over

    The German cockroach's adaption to warm environments, ability to rapidly breed, and unique resistance to insecticides make them a frustratingly common presence in households.

    For example, in a lifetime, one adult female German roach can produce four to eight egg capsules containing up to 48 eggs each, according to Penn State's Department of Entomology. Do the math and that's between 192 to 384 roaches, if every egg survives to adulthood.

    But German roaches didn't migrate thousands of miles across oceans and continents on their tiny insect legs. Their global spread coincides with advancements in human travel and housing, according to the study.

    In particular, the researchers determined that the German cockroach's spread began along two routes, west and east of its origin in India or Myanmar.

    The roach's westward spread likely occurred during times of increasing "commercial and military activities of the Islamic Umayyad or Abbasid Caliphates" about 1,200 years ago, the researchers reported. Meanwhile, the pest's eastward spread about 390 years ago was likely caused by "European colonial commercial activities between South and Southeast Asia."

    Understanding the German cockroaches' origins could help other scientists understand how the species evolved to become so resilient against common insecticides. One study found that they're resistant to five types of common household insecticides.

    "If we can know the origin of the species, we can try to identify the mechanism of this rapid evolution of insecticide resistance," Qian Tang, a research associate at Rowland Institute at Harvard who led the new study told the Post.

    Read the original article on Business Insider
  • 3 top ASX 300 dividend shares to buy now for $3,000 a month in passive income

    Father in the ocean with his daughters, symbolising passive income.

    A $3,000 monthly passive income, or $36,000 a year, would be life-changing for most investors.

    Certainly, I can think of numerous ways I could use that extra cash in retirement. Some of these would be useful, and others would be just a tad extravagant.

    I’m sure you have your own ideas of what you might do with a spare $3,000 a month in passive income.

    With that in mind, we’ll look at three top S&P/ASX 300 Index (ASX: XKO) dividend shares you may want to consider buying today to secure that kind of payout.

    Before we dive into those, though, please keep in mind that the yields you generally see quoted are trailing yields. Future yields may be higher or lower, depending on a range of company-specific and macroeconomic factors.

    Also bear in mind that a well-diversified passive income portfolio should contain more than just three dividend stocks. Investing in a wider basket of companies that operate in different sectors and locations will help to lower the overall risk of your ASX dividend portfolio.

    With that said…

    Three ASX 300 dividend shares for passive income

    The first ASX 300 share I’d buy now to secure my $3,000 in monthly passive income is bank stock Australia and New Zealand Banking Group Ltd (ASX: ANZ).

    ANZ paid a partly franked final dividend of 94 cents per share on 22 December. The big four bank will pay the interim dividend of 83 cents per share on 1 July. (ANZ traded ex-dividend on 13 May, so it’s a bit too late to grab that one!)

    All told, that equates to a full-year payout of $1.77 a share.

    At yesterday’s closing price of $28.43, ANZ shares trade on a partly franked trailing yield of 6.23%.

    The second ASX 300 share I’d buy now for passive income is mining stock Fortescue Metals Group Ltd (ASX: FMG).

    The iron ore miner paid a fully franked final dividend of $1.00 a share on 28 September. The interim dividend of $1.08 a share was paid on 27 March.

    That works out to a 12-month payout of $2.08 a share.

    At yesterday’s closing price of $26.51, that equates to a fully franked trailing yield of 7.85%.

    Which brings us to the third share I’d buy now for my $3,000 monthly passive income stream, Telstra Group Ltd (ASX: TLS).

    Australia’s biggest telco paid a fully franked final dividend of 8.5 cents a share on 30 August. Telstra delivered the interim dividend of 9 cents per share on 28 March. That brings the 12-month payout of 17.5 cents a share.

    At yesterday’s closing price of $3.53 a share, Telstra shares trade on a fully franked trailing yield of 4.96%.

    To the maths!

    Assuming I buy an equal number of shares in each ASX 300 dividend stock, I can expect to earn a yield of 6.3%, largely franked.

    To earn my $3,000 monthly passive income, or $36,000 a year, I’d need to invest $568,421 today.

    Now that’s a sizeable amount to invest in one go.

    But that’s OK.

    Investing is a long game.

    I can also make regular smaller investments. And by tapping into the magic of compounding, I’ll reach my passive income goal in good time.

    The post 3 top ASX 300 dividend shares to buy now for $3,000 a month in passive income appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Australia And New Zealand Banking Group right now?

    Before you buy Australia And New Zealand Banking Group shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Australia And New Zealand Banking Group wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    See The 5 Stocks
    *Returns as of 5 May 2024

    More reading

    Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • 3 things about Qantas stock every smart investor knows

    Man sitting in a plane seat works on his laptop.

    Qantas Airways Limited (ASX: QAN) stock has risen around 20% since the end of February 2024, as shown on the chart below. The ASX travel share has had a rough 12 months, but the future looks more positive.

    The company has made some moves in the last few months to win back the trust of passengers after its ticket-selling misdemeanours. For example, Qantas recently expanded its frequent flyer program by adding 20 million more reward seats.

    There are (at least) three things that investors should know about Qantas stock, which could make it a compelling investment.

    Qantas loyalty division is highly profitable

    Many people may think that flights are the only important part of the business. The Qantas loyalty division is becoming increasingly profitable and a bigger contributor to the company’s overall earnings.

    In the first half of FY24, Qantas made a total underlying profit before tax of $1.25 billion, down 13%.

    It made HY24 underlying earnings before interest and tax (EBIT) in the Qantas domestic division of $641 million, $322 million of underlying EBIT in Qantas international (including freight), $325 million of underlying EBIT in Jetstar Group and $270 million of underlying EBIT in the Qantas Loyalty division. The HY24 Qantas Loyalty underlying EBIT rose by 23% year over year.

    Qantas aims to reach $800 million to $1 billion of underlying EBIT by FY30. This segment could contribute to the ASX travel share’s overall profitability at a greater level in the coming years.

    Share buyback

    A share buyback is one of the most useful things a company can do to increase the value of shares for shareholders.

    The ASX travel share announced in the HY24 result that it was increasing its on-market share buyback by up to $400 million.

    Buying back shares means the company’s value is being shared between a smaller number of shares, increasing the underlying value in per-share terms. This helps shareholder-related metrics such as the return on equity (ROE) and earnings per share (EPS). In theory, it should help push the Qantas stock price higher as the share buyback continues.

    Very cheap valuation

    Airlines usually don’t trade on a high price/earnings (P/E) ratio, but the profit they make is just as valuable as the profit dollars made by an ASX tech share, ASX retail share or ASX bank share.

    In the FY24 first-half result, the business made statutory net profit after tax (NPAT) of $869 million, or statutory EPS of 52 cents.

    The broker UBS has estimated Qantas could generate EPS of 91 cents in FY24, 99 cents in FY27 and $1.11 in FY28. According to those projections, the Qantas stock price is valued at 6.7x FY24’s estimated earnings, 6.2x FY27’s estimated earnings and 5.5x FY28’s estimated earnings.

    In three years from now, Qantas’ profit could be substantially higher, so it looks to me to be at a very appealing level now.

    The post 3 things about Qantas stock every smart investor knows appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Qantas Airways Limited right now?

    Before you buy Qantas Airways Limited shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Qantas Airways Limited wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    See The 5 Stocks
    *Returns as of 5 May 2024

    More reading

    Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • Which ASX biotech shares are pioneering the future of medicine?

    Shot of a young scientist using a digital tablet while working in a lab.

    ASX biotech shares have been showing significant signs of momentum lately. Exciting clinical trial results and strong investor interest are propelling the sector forward. Plenty of upcoming catalysts and company-specific developments could mean the rest of 2024 is also busy for ASX biotech stocks. 

    The biotechnology industry combines biology with technology to develop products for various applications. Biotech stocks are shares in companies developing biotech products, which could have medical, agricultural, or industrial applications. 

    Many biotech firms focus on genetics and molecular biology to innovate. Extensive research and development (R&D) is undertaken to create new therapies and technologies. This means substantial R&D spending generally precedes revenue generation. Success in biotech can lead to significant rewards, however, with share values potentially soaring following technological breakthroughs or drug approvals. 

    Risks and rewards 

    The biotech sector is known for its volatility, driven by the high stakes of clinical trials. The performance of biotech shares tends to be driven by company-specific developments, such as trial data, rather than broader economic factors. This means the sector is generally non-cyclical and can provide potential diversification benefits. 

    The ASX is home to a number of groundbreaking biotech companies pioneering innovative therapies. For example, Telix Pharmaceuticals Ltd (ASX: TLX) develops radiopharmaceutical diagnostic agents and therapeutic products that are reshaping oncological care. Fellow ASX 300 biotech Clinuvel Pharmaceuticals Limited (ASX: CUV) develops treatments for serious skin disorders. Both Clinuvel and Telix have successfully commercialised products and are expanding their market presence. This should bode well for future revenue streams. 

    The ASX also hosts an array of emerging biotech firms that are beginning to make their mark. Botanix Pharmaceuticals Ltd (ASX: BOT) develops dermatological products and drug treatments. The company is preparing for the upcoming commercial launch of a topical treatment for underarm sweating. Federal Drug Administration (FDA) approval for the treatment is expected by late June 2024. 

    Meanwhile, Neuren Pharmaceuticals Ltd (ASX: NEU) is focused on developing treatments for severe neurodevelopmental disorders like Rett syndrome and Fragile X syndrome. It recently achieved FDA approval for a drug that treats Rett syndrome in adults and children over two years old. This is the first and only approved treatment for this condition. Another Neuren Pharmaceuticals drug candidate is also in trials for the treatment of several other disorders. 

    As these companies progress through regulatory pipelines and reach commercial stages, the impact on their valuations could be transformative.  

    What does the future hold for ASX biotech shares? 

    Biotech firms on the ASX are benefitting from global trends that favour advancements in medical technology and increased healthcare demand. The performance of individual biotech companies, however, is ultimately dependent on successful outcomes from R&D activities.
     
    Investing in this sector comes with high volatility and risk, but does offer substantial growth potential. Current trends suggest a positive trajectory for ASX biotech shares, making them an interesting sector for investors looking for exposure to innovative healthcare solutions.

    The post Which ASX biotech shares are pioneering the future of medicine? appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Botanix Pharmaceuticals Limited right now?

    Before you buy Botanix Pharmaceuticals Limited shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Botanix Pharmaceuticals Limited wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    See The 5 Stocks
    *Returns as of 5 May 2024

    More reading

    Motley Fool contributor Katherine O’Brien has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • The little-known ASX tech stock that could rise 25% in a year

    A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares

    The ASX tech stock Siteminder Ltd (ASX: SDR) is a leading opportunity according to one of the top brokers in Australia.

    The company aims to provide software that “unlocks the full revenue potential of hotels”. It’s responsible for more than 115 million reservations worth over $70 billion in revenue for its hotel customers annually. Its all-in-one hotel management software for small accommodation providers is called Little Hotelier.

    There are a number of positives about the company, according to the broker UBS.

    Bullish reasons UBS likes this ASX tech stock

    The broker said there are multiple positives for the company’s outlook following the FY24 third-quarter update.

    First, UBS noted that Siteminder’s underlying free cash flow of negative $0.2 million was close to breakeven. This was consistent with the management’s target of generating positive free cash flow in the second half of FY24.

    The second positive was developments with its new product – ‘Channel Plus’ signed an agreement with Trip.com Group. This means hoteliers can “effortlessly distribute their inventory to the rebounding Chinese outbound tourism market, while Trip.com will gain access to more hotels.” UBS noted that 14 channels have been signed, compared to just six in the FY24 first half. There is “strong initial customer interest” in Siteminder’s new releases, according to UBS.

    The third positive about Siteminder is its product enhancements. The ASX tech share has introduced Siteminder Pay into “new markets”. The company also noted the rollout of Siteminder Pay terminals is on track for the first half of FY25. Little Hotelier Autopay, which was released at the start of the FY24 third quarter, has seen “strong adoption and increased Siteminder’s capture of gross booking value at participating properties.”

    The final positive UBS pointed to about the ASX tech stock was that hotel subscriber additions have continued the momentum from the first half of FY24, which is “skewed towards larger properties”, with the highest room count per hotel added since the COVID-19 reopening. In the broker’s view, this provides higher revenue per subscriber, a larger base for future transactions and higher new product uptake, combined with lower subscriber churn.

    The ASX tech stock is still targeting medium-term revenue growth of 30%. UBS thinks the core offering looks “appealing” and sees potential upside to its estimates if traction for the new product launch is stronger than expected.

    Siteminder share price target

    UBS has a price target of $6.65 on Siteminder shares, which is currently around 25% higher than it is today. A price target is where the broker thinks the Siteminder share price will be in 12 months.

    That positive outlook is despite the Siteminder share price rising around 70% over the past 12 months, as seen on the chart below.

    The post The little-known ASX tech stock that could rise 25% in a year appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Siteminder Limited right now?

    Before you buy Siteminder Limited shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Siteminder Limited wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    See The 5 Stocks
    *Returns as of 5 May 2024

    More reading

    Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended SiteMinder. The Motley Fool Australia has positions in and has recommended SiteMinder. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • Buy this cheap small cap ASX share for a very big return

    If you’re looking for big returns, then it could be worth checking out the small side of the market.

    That’s because in exchange for higher risk, investors have the potential for higher rewards.

    For example, the small cap ASX share in this article has been tipped to provide investors with a return that is more than double the historic market return.

    Let’s see what analysts at Bell Potter are saying about this small cap.

    Which small cap ASX share is a buy?

    According to a note out of Bell Potter, following a change of analyst, the broker has reaffirmed its buy rating and 29 cents price target on Capitol Health Ltd (ASX: CAJ) shares.

    Based on its current share price of 24.5 cents, this implies potential upside of 18% for investors over the next 12 months.

    In addition, the broker is expecting the medical imaging company to pay fully franked dividends of 1 cent per share in FY 2024, FY 2025, and FY 2026. This will mean dividend yields of 4.1% each year, boosting the total potential return to over 22%.

    To put that into context, a $10,000 would be worth approximately $12,200 in 12 months if Bell Potter’s recommendation proves accurate.

    It is also more than double the historical return of the share market, which sits at around 10% per annum.

    Why is it bullish?

    The note reveals that Bell Potter has boosted its revenue estimates for the coming years. This is to reflect the normalising of volumes and pricing growth rates. And while the broker expects inflationary pressures to weigh on margins in the near term, it appears to believe that this is more than priced into the small cap ASX share’s valuation at present. It commented:

    On the transfer of coverage, we have reviewed our earnings estimates. Across FY24e – FY26e, we have increased our revenue estimates by c.1.6% / c.4.7% / c.7.9% driven by normalising volume and pricing growth rates across DI Services and Benefits. However, we expect inflationary pressures to dampen the recovery in operating margins and a lower plateau than previous estimates with margins levelling out at c.22% by FY28e.

    This leads to a cut in earnings expectations of c.-8% / c-4.8% / c.- 13.4%. We have upgraded our blended DCF / EV / EBITDA valuation by c.3.6% to $0.29 / sh, reflecting adjustments in our valuation parameters. Catalysts for the share price include continued positive momentum in the Medicare data and M&A activity.

    The post Buy this cheap small cap ASX share for a very big return appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Capitol Health Limited right now?

    Before you buy Capitol Health Limited shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Capitol Health Limited wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    See The 5 Stocks
    *Returns as of 5 May 2024

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • ASX investors may choose supermarkets over Wesfarmers shares after ACCC inquiry: broker

    A female Woolworths customer leans on her shopping trolley as she rests her chin in her hand thinking about what to buy for dinner while also wondering why the Woolworths share price isn't doing as well as Coles recently

    Wesfarmers Ltd (ASX: WES) shares have had an impressive run of share price growth over the past year.

    Yesterday, the market’s biggest consumer discretionary share closed at $64.61, up 1.24% for the day, and up 31.7% over the past 12 months.

    After such a strong run, top broker Goldman Sachs reckons Wesfarmers shares may lose some investor support to ASX supermarket shares, given their attractive valuations these days.

    Wesfarmers shares downgraded by top broker

    On Friday, Goldman Sachs downgraded Wesfarmers shares from a buy rating, which it assigned to the stock on 25 January, to a neutral rating.

    The 12-month price target remains unchanged at $68.80.

    Analysts Lisa Deng and James Leigh explained that their earnings expectations for the conglomerate have not changed, but their buy thesis has now “played out”.

    They also commented that Wesfarmers shares may lose some support from investors in favour of fallen ASX supermarket shares amid the Australian Competition and Consumer Commission (ACCC) inquiry.

    The ACCC inquiry is examining supermarkets’ pricing practices and the relationship between wholesale, including farmgate, and retail prices. Essentially, it seeks to determine whether supermarkets are price-gouging customers. An interim report is due by 31 August, and a final report is due by 28 February 2025.

    What’s happening with ASX supermarket shares?

    The two major supermarket shares on the ASX are Woolworths Group Ltd (ASX: WOW) and Coles Group Ltd (ASX: COL).

    There’s also ASX mid-cap stock Metcash Ltd (ASX: MTS), which owns the IGA and Foodland grocery store networks, the Cellarbrations, Porters Liquor and Bottle-O liquor brands, and the Mitre 10 chain.

    While Deng and Leigh do not name specific supermarket stocks, they point out that they are trading at historically attractive prices.

    The analysts said:

    As the supermarket ACCC inquiry concludes, we expect the regulatory overhang on supermarkets to dissipate, potentially drawing capital away from WES given the supermarkets’ more attractive valuation.

    What’s the P/E comparison to Wesfarmers shares?

    According to CBA data, Wesfarmers shares are trading on a price-to-earnings (P/E) ratio of 28.7x.

    This compares to Woolworths shares at 22.1x, Coles shares at 20.17x, and Metcash shares at 13.85x.

    Over the past 12 months, Woolworths shares have fallen 17.67% to close at $31.46 yesterday. Goldman Sachs has a buy rating on Woolworths shares with a 12-month price target of $39.40.

    Coles shares have fallen 10.32% to $16.34. The broker has a neutral rating and a price target of $16.30 on the stock.

    Metcash shares have gained 4.66% in value over the past year and closed at $3.82 apiece yesterday. Goldman has a neutral rating on Metcash shares with a price target of $3.70.

    As mentioned earlier, Wesfarmers shares have gained 31.7% over the past 12 months.

    Other inquiries into the supermarkets

    Apart from the ACCC inquiry, others have also taken place concurrently.

    A Senate Select Committee on Supermarket Prices handed down its report earlier this month.

    Its recommendations included creating divestiture powers in the supermarket sector and giving the ACCC the authority to investigate and prosecute unfair trading practices.

    Meantime, a formal review of the Food and Grocery Code of Conduct is also underway.

    The code’s purpose is “to address harmful practices in the grocery sector stemming from an imbalance of bargaining power between supermarkets and their suppliers”.

    A final report is due on 30 June.

    The post ASX investors may choose supermarkets over Wesfarmers shares after ACCC inquiry: broker appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Coles Group Limited right now?

    Before you buy Coles Group Limited shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Coles Group Limited wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    See The 5 Stocks
    *Returns as of 5 May 2024

    More reading

    Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Wesfarmers. The Motley Fool Australia has positions in and has recommended Coles Group and Wesfarmers. The Motley Fool Australia has recommended Metcash. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.